Gilead Sciences was founded in 1987 in Foster City, California, by a brilliant, 29-year-old physician named Michael L. Riordan. The foundational premise of the tiny biotech startup was specific and contrarian: focusing entirely on antiviral drugs. At the time, the vast majority of the considerable pharmaceutical industry viewed antivirals as essentially impossible to commercialize. However, under the aggressive, focused leadership of CEO John C. Martin, Gilead built an, dominant global monopoly in the treatment of HIV/AIDS, creating effective, single-pill daily regimens (like Atripla) that essentially transformed HIV from a fatal diagnosis into a manageable chronic condition.
The Pharmasset Acquisition (The $11 Billion Gamble)
In 2011, Gilead executed arguably the most successful, risky strategic acquisition in the history of the pharmaceutical industry. They acquired Pharmasset (a tiny, major cash-burning biotech startup) for a staggering $11.2 billion. Wall Street analysts were horrified, believing Gilead had recklessly overpaid. Pharmasset possessed essentially no revenue, but they had a promising, experimental oral drug designed to treat Hepatitis C (Hep C). Gilead management, however, recognized that this single drug had the potential to alter the global medical landscape.
Sovaldi and Harvoni (The Cure and The Controversy)
The resulting drugs (Sovaldi and Harvoni) were approved in 2013 and 2014. They were primary, unprecedented medical miracles: a 12-week course of tolerable pills that physically cured Hepatitis C in over 95% of patients. The financial result was a true, astronomical explosion. In 2015 alone, Gilead generated a staggering $32 billion in revenue. However, the drugs sparked a considerable, explosive global controversy regarding drug pricing. A single pill of Sovaldi cost $1,000 (meaning the 12-week cure cost $84,000). aggressive politicians and significant insurance companies attacked Gilead, accusing them of corporate greed, despite Gilead arguing the drug was cheaper than a complex, multi-million-dollar liver transplant.
The Curse of the Cure (The Revenue Collapse)
Gilead then suffered the ironic, frustrating corporate problem of actually being too successful. Because Harvoni literally cured the disease, the patient did not need to buy the drug for the rest of their life (unlike HIV medication or insulin). As Gilead rapidly cured the most severe Hep C patients, the considerable, astronomical revenue violently collapsed. Wall Street punished the stock. Gilead was sitting on tens of billions of dollars in lucrative cash, but its extensive revenue growth was dead, forcing the company to desperately search for a new growth engine.
The Pivot to Oncology (Kite Pharma and Immunomedics)
To survive and replace the significant, lost Hep C revenue Gilead is currently executing an aggressive, multi-billion-dollar strategic pivot into Oncology (cancer). Under CEO Daniel O'Day, Gilead has executed extensive, expensive acquisitions. In 2017, they bought Kite Pharma for $11.9 billion to dominate advanced CAR-T cell therapy. In 2020, they acquired Immunomedics for an astonishing $21 billion to acquire Trodelvy (a lucrative breast cancer drug). Gilead is desperately attempting to prove to Wall Street that it can transform its, dominant antiviral DNA into a diversified, substantial global cancer leviathan.
